| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Duncan Jason, Chief Legal & Admin Officer
Granted 500,000 Stock Option (Right to Buy) |
| 13 Nov 2026 |
Form 3: Duncan Jason, Chief Legal & Admin Officer
Holds 0 shares of No securities beneficially held |
| 13 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of... |
| 24 Sep 2026 |
Form 4: Grossman William, Director
Bought 5,102 shares ($10.1K) |
| 08 Sep 2026 | 10-Q |
| 08 Sep 2026 |
8-K: Results of Operations and Financial Condition
Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 |
8-K: Other Events
Non-Viral Genetic Medicine Virtual KOL Event: Emerging NMIBC Market Insights August 11, 2026 |
| 22 Jul 2026 | Form 3: Chinoporos Constantine, Interim Chief Business Officer |
| 22 Jul 2026 |
Form 3: Richton Kathleen P., SVP, Finance and Treasurer
Holds 6,900 shares of Common Shares |
| 22 Jul 2026 | SCHEDULE 13G |
| 17 Jul 2026 |
8-K: Regulation FD Disclosure
Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of... |
| 16 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026 |
| 18 Jun 2026 |
8-K/A: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation
As previously disclosed in the Company’s Original Form 8-K, effective June 14, 2026, the Company’s board of directors (the “Board”) approved a plan to reduce the Company’s workforce by approximately 50% to streamline operations and prese... |
| 17 Jun 2026 |
Form 4: Astley-Sparke Philip, Director
Granted 31,000 Stock Option (Right to Buy) |
Loading...